A hazard ratio of 0.41 is a striking number in a disease where salvage options have historically delivered median progression-free survival measured in weeks, not months. The FDA’s acceptance of Roche’s supplemental BLA for subcutaneous Lunsumio VELO plus Polivy in relapsed or refractory large B-cell lymphomaB-cell lymphoma puts a February 9, 2027 decision date on the calendar, and the clinical story anchoring that filing is worth examining closely. In the phase III SUNMO study, the combination produced a median PFS of 11.5 months against 3.8 months for R-GemOx at a median follow-up of 23.2 months, a three-fold difference that held up with longer follow-up data presented at both ASCO and EHA this year.
The design detail that shapes the regulatory and clinical argument here is transplant ineligibility. SUNMO enrolled patients with relapsed or refractory LBCL who are not candidates for autologous stem cell transplant, a population that has seen genuine therapeutic movement recently. Brentuximab vedotin with lenalidomide and rituximab received FDA approval in early 2025 for the same transplant-ineligible LBCL population, and Roche’s own glofitamab-based regimen from the STARGLO study demonstrated an overall survival benefit in a similar R/R DLBCL setting. The combination under review here offers something none of those approved regimens foreground as a structural feature: a fully subcutaneous bispecific paired with an antibody-drug conjugate, designed to function in community oncology practices without the logistical footprint of inpatient or transplant-center infrastructure. With more than 18,000 new LBCL diagnoses annually in the US and roughly 40% of patients eventually relapsing, the volume of patients who never reach academic centers is not a niche concern.
The safety profile adds a meaningful clinical dimension. CRS occurred in approximately one in four patients in the Lunsumio VELO plus Polivy arm, but fewer than 5% experienced Grade 2 or 3 events. That low rate of high-grade CRS is what makes outpatient administration genuinely credible rather than aspirational. Lunsumio IV received accelerated approval in December 2022 for relapsed or refractory follicular lymphoma, and Polivy has carried an LBCL indication since 2019, so both agents have established safety records the FDA will weigh against these combination data. The question the SUNMO dataset still needs to answer clearly is overall survival, listed as a secondary endpoint, and whether the PFS advantage translates into an OS signal durable enough to satisfy a post-accelerated-approval standard if the agency requests it.
The single marker worth tracking between now and the February decision is the OS data readout from SUNMO. PFS at 11.5 months is clinically meaningful, but in a regulatory environment increasingly attentive to survival endpoints in hematologic malignancies, an OS signal would cement the filing and distinguish this regimen from a crowded and rapidly evolving second-line LBCL landscape.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
